Fujiedas Imoto News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Search jobs
16-Dec-2020
First patients dosed in Phase III trials evaluating Fasenra in hypereosinophilic syndrome, eosinophilic esophagitis and eosinophilic granulomatosis with polyangiitis
New clinical trial also announced for Fasenra
in eosinophilic gastritis/eosinophilic gastroenteritis
The first patients have been dosed in
Fasenra (benralizumab) Phase III trials in three rare eosinophilic diseases: hypereosinophilic syndrome (HES), eosinophilic esophagitis (EoE) and eosinophilic granulomatosis with polyangiitis (EGPA)
AstraZeneca will also initiate a Phase III trial to investigate the potential of
Fasenra in an additional rare eosinophilic disease: eosinophilic gastritis/eosinophilic gastroenteritis (EG/EGE). This trial extends the
Fasenra clinical programme to nine diseases where eosinophils play an important role, in addition to severe asthma. ....

United Kingdom , United States , Clin Otolaryngol , Bachertc Biologics , Wechslerm Akuthota , Fujiedas Imoto , Pediatr Gastroenterol Nutr , Gastroenterol Hepatol , Company On Twitter , Glob Health Epidemiol Genom , Global Health Epidemiology Reference Group , Wales National , Biowa Inc , Kyowa Kirin Co Ltd , Global Initiative For Chronic Obstructive Lung Disease , Vasculitis Foundation , Drug Administration , Impact On Health , American Academy Of Allergy Asthma Immunology , Investor Relations Team , National Organisation For Rare Disorders , J Glob Health , American Partnership For Eosinophilic Disorders , Executive Vice President , Orphan Drug Designation , Churg Strauss Syndrome ,